ADC Therapeutics (ADCT) Other Non-Current Assets (2019 - 2026)
ADC Therapeutics (ADCT) posted Other Non-Current Assets of $1.2 million for Q1 2026, up 2.38% sequentially from $1.2 million in Q4 2025, and up 7.14% YoY from $1.2 million in Q1 2025.
ADC Therapeutics (ADCT) Other Non-Current Assets (2019 - 2026) Analysis & Trends
ADC Therapeutics has reported Other Non-Current Assets for 8 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 7.14% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 7.14% YoY) and the FY2025 annual result came in at $1.2 million, up 4.82% from the prior year.
- Other Non-Current Assets climbed to $1.2 million in Q1 2026 per ADCT's latest filing, from $1.2 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.4 million in Q2 2023 and troughed at $711000.0 in Q4 2023.
- A 5-year average of $1.1 million and a median of $1.2 million in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets jumped 160.71% in 2022, then sank 31.25% in 2024.
- Over 5 years, Other Non-Current Assets stood at $902000.0 in 2022, then dropped by 21.18% to $711000.0 in 2023, then soared by 63.29% to $1.2 million in 2024, then rose by 4.82% to $1.2 million in 2025, then gained by 2.38% to $1.2 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.2 million, $1.2 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | 1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.24 Mn |
| Mar 31, 2026 | 1.25 Mn |
| Dec 31, 2025 | 1.22 Mn |
| Sep 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 1.16 Mn |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 992,000.00 |
| Mar 31, 2024 | 986,000.00 |
| Dec 31, 2023 | 711,000.00 |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 1.44 Mn |
| Mar 31, 2023 | 1.23 Mn |
| Dec 31, 2022 | 902,000.00 |
| Sep 30, 2022 | 899,000.00 |
| Jun 30, 2022 | 899,000.00 |
| Mar 31, 2022 | 1.02 Mn |
| Dec 31, 2021 | 693,000.00 |
| Sep 30, 2021 | 691,000.00 |